2Cortes JE, Kantarjian HM, Goldberg SL, et al. High-do- es imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses[J]. J Clin Oncol, 2009,27 (28) : 4 754.
3Sissung TM, Thordardottir S, Gardner ER, et al. Current status of thalidomide and CC-5013 in the treatment of met- astatic prostate cancer[J]. Anti-cancer Agents in Medicinal Chemistry, 2009, 9(10):1 058.
4Kastritis E, Palumbo A, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma[J]. Seminars in He- matology, 2009, 46(2):143.
5Laubach JP, Schlossman RL, Mitsiades CS, et al. Thalid- omide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma[J]. Expert Review of Hematology, 2011,4(1) :51.
6Du GJ, Lin HH, Xu QT, et al. Thalidomide inhibits gro- wth of tumors through COX-2 degradation independent of antiangiogenesis[J]. Vascular Pharmacology, 2005, 43 (2):112.
